pyrazinamide has been researched along with Abetalipoproteinemia in 1 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Abetalipoproteinemia: An autosomal recessive disorder of lipid metabolism. It is caused by mutation of the microsomal triglyceride transfer protein that catalyzes the transport of lipids (TRIGLYCERIDES; CHOLESTEROL ESTERS; PHOSPHOLIPIDS) and is required in the secretion of BETA-LIPOPROTEINS (low density lipoproteins or LDL). Features include defective intestinal lipid absorption, very low serum cholesterol level, and near absent LDL.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simpson, AJ | 1 |
| Mirza, AM | 1 |
| Martin, JF | 1 |
| O'Brien, TF | 1 |
1 other study available for pyrazinamide and Abetalipoproteinemia
| Article | Year |
|---|---|
Hepatitis secondary to pyrazinamide toxicity: accompaniments of transient hypolipoproteinemia, acanthocytosis, and changes in stomach and small bowel.
Topics: Abetalipoproteinemia; Adult; Chemical and Drug Induced Liver Injury; Erythrocytes, Abnormal; Female; | 1970 |